Novavax, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Novavax, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-13.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 54% of Healthcare companies in United States.
Cash Locked Ratio
$8For every $100 of sales, $8 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $6 from others' credit three years earlier.
Less money tied up than 83% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 30%
Sales fell 30% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-30% / -48%In 3 years sales changed by -30% while total assets changed by -48%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-97.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 82% of Healthcare companies in United States.
Cash Cushion Ratio
+30%Cash, after subtracting all debt, equals 30% of its market value (net cash).
Higher than 68% of Healthcare companies in United States.
Tangible Assets Ratio
90%Of every $100 the company owns, $90 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 63% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Novavax, Inc. made a loss over the last year. Novavax, Inc. owes $1.20 for every $1 it owns. Novavax, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNovavax, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-8.64Novavax, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$1.6 BThe total market value of all of Novavax, Inc.'s shares at today's price (share price × number of shares), larger than 71% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeNovavax, Inc.'s net worth is negative ($191 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.20×Novavax, Inc. owes $1.20 for every $1 it owns, so it owes more than it owns, higher than 91% of Healthcare companies in United States.
Dividend yield
NoneNovavax, Inc. does not currently pay a dividend.
Revenue growth
+65%Revenue rose 65% in the year to Dec 2025, and shrank 11% a year on average over 3 years.
Profit growth
Back to profitNovavax, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
39.2%Novavax, Inc. keeps $39 of every $100 of revenue as net profit.
Cash quality
-0.6×Cash from Novavax, Inc.'s business was -0.6× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
24.4×Novavax, Inc.'s operating profit covered its interest costs 24.4 times in the year to Dec 2025.
Cash vs debt
Net cashNovavax, Inc. held $486 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Novavax, Inc. owe compared with what it owns?
Novavax, Inc. owes $1.20 for every $1 it owns, so it owes more than it owns, higher than 91% of Healthcare companies in United States.
Does Novavax, Inc. pay a dividend?
No. Novavax, Inc. does not currently pay a dividend.
Is Novavax, Inc.'s revenue growing?
Revenue rose 65% in the year to Dec 2025, and shrank 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.